Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 19:14:853277.
doi: 10.3389/fnagi.2022.853277. eCollection 2022.

Genetic Variability of the Vitamin D Receptor Affects Susceptibility to Parkinson's Disease and Dopaminergic Treatment Adverse Events

Sara Redenšek  1 , Tilen Kristanc  1 , Tanja Blagus  1 , Maja Trošt  2 , Vita Dolžan  1
Affiliations

Genetic Variability of the Vitamin D Receptor Affects Susceptibility to Parkinson's Disease and Dopaminergic Treatment Adverse Events

Sara Redenšek et al. Front Aging Neurosci. .

Abstract

Vitamin D is a lipid-soluble molecule and an important transcriptional regulator in many tissues and organs, including the brain. Its role has been demonstrated also in Parkinson's disease (PD) pathogenesis. Vitamin D receptor (VDR) is responsible for the initiation of vitamin D signaling cascade. The aim of this study was to assess the associations of VDR genetic variability with PD risk and different PD-related phenotypes. We genotyped 231 well characterized PD patients and 161 healthy blood donors for six VDR single nucleotide polymorphisms, namely rs739837, rs4516035, rs11568820, rs731236, rs2228570, and rs1544410. We observed that VDR rs2228570 is associated with PD risk (p < 0.001). Additionally, we observed associations of specific VDR genotypes with adverse events of dopaminergic treatment. VDR rs1544410 (GG vs. GA + AA: p = 0.005; GG vs. GA: p = 0.009) was associated with the occurrence of visual hallucinations and VDR rs739837 (TT vs. GG: p = 0.036), rs731236 (TT vs. TC + CC: p = 0.011; TT vs. TC: p = 0.028; TT vs. CC: p = 0.035), and rs1544410 (GG vs. GA: p = 0.014) with the occurrence of orthostatic hypotension. We believe that the reported study may support personalized approach to PD treatment, especially in terms of monitoring vitamin D level and vitamin D supplementation in patients with high risk VDR genotypes.

Keywords: Parkinson’s disease; adverse events; biomarker; polymorphism; risk; susceptibility; vitamin D; vitamin D receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Agliardi C., Guerini F. R., Zanzottera M., Bolognesi E., Meloni M., Riboldazzi G., et al. (2021). The VDR FokI (rs2228570) polymorphism is involved in Parkinson’s disease. J. Neurol. Sci. 428:117606. - PubMed
    1. Arai H., Miyamoto K., Taketani Y., Yamamoto H., Iemori Y., Morita K., et al. (1997). A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12 915–921. 10.1359/jbmr.1997.12.6.915 - DOI - PubMed
    1. Chitsaz A., Maracy M., Basiri K., Izadi Boroujeni M., Tanhaei A. P., Rahimi M., et al. (2013). 25-hydroxyvitamin d and severity of Parkinson’s disease. Int. J. Endocrinol. 2013:689149. - PMC - PubMed
    1. Colin E. M., Weel A. E., Uitterlinden A. G., Buurman C. J., Birkenhäger J. C., Pols H. A., et al. (2000). Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. 52 211–216. 10.1046/j.1365-2265.2000.00909.x - DOI - PubMed
    1. Dehestani M., Liu H., Gasser T. (2021). Polygenic Risk scores contribute to personalized medicine of Parkinson’s disease. J. Pers. Med. 11:1030. 10.3390/jpm11101030 - DOI - PMC - PubMed

LinkOut - more resources